Cochrane · systematic review · CD008521
Vaccines for preventing rotavirus diarrhoea: vaccines in use
Bergman, H, Henschke, N, Hungerford, D, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
56
current version
GRADE rated
50
No studies
6
Included studies
NR
No studies 6 · 10.7%Ungraded 0 · 0%Very low 5 · 8.9%Low 10 · 17.9%Moderate 13 · 23.2%High 22 · 39.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 5 versionsRotarix compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.07 [0.03, 0.18] | 4 studies · 14976 participants | High |
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.1 [0.07, 0.14] | 6 studies · 18145 participants | High |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.48 [0.37, 0.61] | 1 study · 3874 participants | Moderate Downgraded: risk of bias, imprecision |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.49 [0.4, 0.6] | 2 studies · 6269 participants | Moderate Downgraded: risk of bias, imprecision |
All‐cause death Rotarix vs placebo | RR 0.71 [0.17, 2.88] | 10 studies · 20361 participants | Low Downgraded: imprecision |
All serious adverse events Rotarix vs placebo | RR 0.89 [0.72, 1.1] | 12 studies · 18971 participants | High |
Serious adverse events: intussusception Rotarix vs placebo | RR 1.42 [0.52, 3.87] | 10 studies · 20773 participants | Low Downgraded: imprecision |
Rotarix compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.21 [0.16, 0.29] | 4 studies · 31671 participants | High |
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.23 [0.17, 0.29] | 3 studies · 23834 participants | High |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.64 [0.52, 0.79] | 2 studies · 26479 participants | High |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.74 [0.5, 1.09] | 2 studies · 23317 participants | Low Downgraded: imprecision, inconsistency |
All‐cause death Rotarix vs placebo | RR 1.27 [0.89, 1.81] | 9 studies · 77043 participants | Moderate Downgraded: imprecision |
All serious adverse events Rotarix vs placebo | RR 0.85 [0.76, 0.95] | 9 studies · 77069 participants | High |
Serious adverse events: intussusception Rotarix vs placebo | RR 0.72 [0.39, 1.32] | 6 studies · 75540 participants | Low Downgraded: imprecision |
Rotarix compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.42 [0.28, 0.61] | 4 studies · 15822 participants | High |
Severe cases of rotavirus diarrhoea Rotarix vs placebo | RR 0.65 [0.51, 0.83] | 2 studies · 13768 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.73 [0.56, 0.95] | 2 studies · 5639 participants | High |
Severe cases of all‐cause diarrhoea Rotarix vs placebo | RR 0.83 [0.72, 0.96] | 1 study · 2764 participants | High |
All‐cause death Rotarix vs placebo | RR 0.88 [0.63, 1.21] | 11 studies · 8374 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
All serious adverse events Rotarix vs placebo | RR 0.9 [0.77, 1.05] | 10 studies · 7674 participants | High |
Serious adverse events: intussusception Rotarix vs placebo | RR 1.49 [0.06, 36.63] | 5 studies · 17068 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
RotaTeq compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | RR 0.03 [0.01, 0.11] | 5 studies · 7688 participants | High |
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | RR 0.04 [0.01, 0.11] | 2 studies · 5442 participants | High |
Severe all‐cause diarrhoea RotaTeq vs placebo | no estimate extracted | NR | No studies |
Severe all‐cause diarrhoea RotaTeq vs placebo | no estimate extracted | NR | No studies |
All‐cause death RotaTeq vs placebo | RR 1.24 [0.69, 2.22] | 6 studies · 72654 participants | Low Downgraded: imprecision |
All serious adverse events RotaTeq vs placebo | RR 0.92 [0.84, 1.01] | 5 studies · 70690 participants | High |
Serious adverse events: intussusception RotaTeq vs placebo | RR 0.69 [0.35, 1.38] | 9 studies · 73925 participants | Low Downgraded: imprecision |
RotaTeq compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | no estimate extracted | NR | No studies |
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | RR 0.21 [0.11, 0.41] | 1 study · 3863 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Severe all‐cause diarrhoea RotaTeq vs placebo | no estimate extracted | NR | No studies |
Severe all‐cause diarrhoea RotaTeq vs placebo | no estimate extracted | NR | No studies |
All‐cause death RotaTeq vs placebo | RR 0.33 [0.01, 8.18] | 2 studies · 4088 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
All serious adverse events RotaTeq vs placebo | RR 0.66 [0.14, 3.17] | 2 studies · 4082 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events: intussusception RotaTeq vs placebo | RR 5.01 [0.24, 104.29] | 2 studies · 4082 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
RotaTeq compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | RR 0.43 [0.29, 0.64] | 2 studies · 6775 participants | High |
Severe cases of rotavirus diarrhoea RotaTeq vs placebo | RR 0.56 [0.41, 0.77] | 2 studies · 6744 participants | High |
Severe cases of all‐cause diarrhoea RotaTeq vs placebo | RR 0.8 [0.58, 1.11] | 1 study · 4085 participants | Moderate Downgraded: imprecision |
Severe cases of all‐cause diarrhoea RotaTeq vs placebo | RR 0.85 [0.74, 0.99] | 2 studies · 5977 participants | High |
All‐cause death RotaTeq vs placebo | RR 0.91 [0.68, 1.23] | 3 studies · 7706 participants | Moderate Downgraded: imprecision |
All serious adverse events RotaTeq vs placebo | RR 0.99 [0.72, 1.36] | 4 studies · 7730 participants | Moderate Downgraded: imprecision |
Serious adverse events: intussusception RotaTeq vs placebo | RR 0.33 [0.01, 8.16] | 2 studies · 7488 participants | Low Downgraded: imprecision |
Rotasiil compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotasiil vs placebo | RR 0.52 [0.33, 0.81] | 2 studies · 11008 participants | High |
Severe cases of rotavirus diarrhoea Rotasiil vs placebo | RR 0.56 [0.42, 0.74] | 2 studies · 11008 participants | High |
Severe cases of all‐cause diarrhoea Rotasiil vs placebo | RR 0.92 [0.84, 1.01] | 2 studies · 11008 participants | High |
Severe cases of all‐cause diarrhoea Rotasiil vs placebo | RR 0.94 [0.88, 1.01] | 2 studies · 11008 participants | High |
All‐cause death Rotasiil vs placebo | RR 1.14 [0.82, 1.59] | 2 studies · 11586 participants | Moderate Downgraded: imprecision |
All serious adverse events Rotasiil vs placebo | RR 0.98 [0.92, 1.04] | 3 studies · 11646 participants | High |
Serious adverse events: intussusception Rotasiil vs placebo | RR 0.98 [0.35, 2.74] | 2 studies · 11586 participants | Low Downgraded: imprecision |
Rotavac compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries
Population: children
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe cases of rotavirus diarrhoea Rotavac vs placebo | RR 0.43 [0.3, 0.6] | 1 study · 6799 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of rotavirus diarrhoea Rotavac vs placebo | RR 0.46 [0.35, 0.6] | 1 study · 6541 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of all‐cause diarrhoea Rotavac vs placebo | RR 0.84 [0.71, 0.98] | 1 study · 6799 participants | Moderate Downgraded: imprecision, indirectness |
Severe cases of all‐cause diarrhoea Rotavac vs placebo | no estimate extracted | NR | No studies |
All‐cause death Rotavac vs placebo | RR 0.88 [0.5, 1.56] | 2 studies · 8155 participants | Very low Downgraded: imprecision, indirectness |
All serious adverse events Rotavac vs placebo | RR 0.93 [0.85, 1.02] | 3 studies · 8210 participants | Moderate Downgraded: imprecision, indirectness |
Serious adverse events: intussusception Rotavac vs placebo | RR 1.33 [0.35, 5.02] | 4 studies · 8582 participants | Very low Downgraded: imprecision, indirectness |